Yago Tadayuki, Tsukamoto Hiroki, Liu Zhenghui, Wang Ying, Thompson Linda F, McEver Rodger P
Cardiovascular Biology Program, Oklahoma Medical Research Foundation, Oklahoma City, OK 73104;
Immunobiology and Cancer Program, Oklahoma Medical Research Foundation, Oklahoma City, OK 73104; Laboratory of Oncology, Pharmacy Practice and Sciences, Graduate School of Pharmaceutical Sciences, Tohoku University, Sendai 980-8578, Japan;
J Immunol. 2015 Oct 15;195(8):3880-9. doi: 10.4049/jimmunol.1500775. Epub 2015 Sep 9.
A2A adenosine receptor (A2AAR) signaling negatively regulates inflammatory responses in many disease models, but the detailed mechanisms remain unclear. We used the selective A2AAR agonist, ATL313, to examine how A2AAR signaling affects human and murine neutrophil adhesion under flow. Treating neutrophils with ATL313 inhibited selectin-induced, β2 integrin-dependent slow rolling and chemokine-induced, β2 integrin-dependent arrest on ICAM-1. ATL313 inhibited selectin-induced β2 integrin extension, which supports slow rolling, and chemokine-induced hybrid domain "swing-out," which supports arrest. Furthermore, ATL313 inhibited integrin outside-in signaling as revealed by reduced neutrophil superoxide production and spreading on immobilized anti-β2 integrin Ab. ATL313 suppressed selectin-triggered activation of Src family kinases (SFKs) and p38 MAPK, chemokine-triggered activation of Ras-related protein 1, and β2 integrin-triggered activation of SFKs and Vav cytoskeletal regulatory proteins. ATL313 activated protein kinase A and its substrate C-terminal Src kinase, an inhibitor of SFKs. Treating neutrophils with a protein kinase A inhibitor blocked the actions of ATL313. In vivo, ATL313-treated neutrophils rolled faster and arrested much less frequently in postcapillary venules of the murine cremaster muscle after TNF-α challenge. Furthermore, ATL313 markedly suppressed neutrophil migration into the peritoneum challenged with thioglycollate. ATL313 did not affect A2AAR-deficient neutrophils, confirming its specificity. Our findings provide new insights into the anti-inflammatory mechanisms of A2AAR signaling and the potential utility of A2AAR agonists in inflammatory diseases.
A2A 腺苷受体(A2AAR)信号传导在许多疾病模型中对炎症反应起负调节作用,但其详细机制仍不清楚。我们使用选择性 A2AAR 激动剂 ATL313 来研究 A2AAR 信号传导如何影响流动状态下人和小鼠中性粒细胞的黏附。用 ATL313 处理中性粒细胞可抑制选择素诱导的、β2 整合素依赖性的缓慢滚动以及趋化因子诱导的、β2 整合素依赖性的在细胞间黏附分子-1(ICAM-1)上的停滞。ATL313 抑制了选择素诱导的支持缓慢滚动的 β2 整合素伸展以及趋化因子诱导的支持停滞的混合结构域“摆动”。此外,如通过减少中性粒细胞超氧化物产生和在固定化抗 β2 整合素抗体上的铺展所显示的,ATL313 抑制了整合素由外向内的信号传导。ATL313 抑制了选择素触发的 Src 家族激酶(SFKs)和 p38 丝裂原活化蛋白激酶(MAPK)的激活、趋化因子触发的 Ras 相关蛋白 1 的激活以及 β2 整合素触发的 SFKs 和 Vav 细胞骨架调节蛋白的激活。ATL313 激活了蛋白激酶 A 及其底物 C 末端 Src 激酶,后者是 SFKs 的抑制剂。用蛋白激酶 A 抑制剂处理中性粒细胞可阻断 ATL313 的作用。在体内,用 TNF-α 攻击后,经 ATL313 处理的中性粒细胞在小鼠提睾肌的毛细血管后微静脉中滚动得更快且停滞频率显著降低。此外,ATL313 显著抑制了硫代乙醇酸盐攻击后中性粒细胞向腹膜的迁移。ATL313 不影响 A2AAR 缺陷的中性粒细胞,证实了其特异性。我们的研究结果为 A2AAR 信号传导的抗炎机制以及 A2AAR 激动剂在炎症性疾病中的潜在应用提供了新的见解。